A Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Outcomes are poor for older patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), or relapsed/refractory disease, and new therapies are needed. Using a chemosensitivity screening assay, we previously demonstrated that thioguanine/decitabine (TG-D) combinations can rescue therapeutic efficacy in primary leukemia cells isolated from patients with relapsed/refractory AML.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Daniel Lee, Todd Rosenblat, Mark Heaney, Joseph Jurcic, Azra Raza, Katherine Harwood, Ryan Shelton, Hakim Djaballah, Joseph Scandura, Anthony Letai, Mark Frattini Source Type: research